2016 Press Releases| Newsroom | Medtronic

2016 Press Releases


201620152014201320122011
Search News Releases
 
DateTitle  
02/12/16NICE Recommends Medtronic Integrated Sensor-Augmented Insulin Pump As the Only Therapy System to Manage Glucose Levels in Type 1 Diabetes
The NICE guidance reviewed two sensor-augmented insulin pump therapy systems and recommends the MiniMed® Paradigm Veo(TM) system for managing glucose levels in people with Type 1 diabetes.1 The MiniMed Paradigm Veo and the MiniMed 640G sensor-augmented insulin pump therapy systems can help to protect against severe hypoglycemia in people with Type 1 diabetes by continuously monitoring glucose levels. NICE concluded that the adoption of Medtronic technology has the potential to save a UK health s... 
Download PDFPrinter Friendly Version
02/09/16First Patient Treated with Medtronic Valiant TAAA Stent Graft System in Thoracoabdominal Aortic Aneurysm Study
Sanford Health in Collaboration with Medtronic Leads Global Efforts to Address Challenging Vascular Condition DUBLIN and SIOUX FALLS, S.D. - February 9, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions and Sanford Health, one of the nation's largest health care systems, today announced the first patient enrolled in a clinical study using the Medtronic Valiant® TAAA Stent Graft System for minimally invasive repair of thoracoabdominal aortic aneurysm.... 
Download PDFPrinter Friendly Version
02/05/16Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes
iPro2 Professional CGM Provides Information to Help Physicians Optimize Care for Their Patients Regardless of Their Diabetes Therapy MILAN - February 5, 2016 - A retrospective analysis of the iPro2 Professional CGM from Medtronic plc (NYSE:MDT), the global leader in medical technology, demonstrates that patients with type 2 diabetes experience high rates of glycemic variability, hypoglycemia and hyperglycemia regardless of whether they manage their diabetes with diet/exercise, oral medication o... 
Download PDFPrinter Friendly Version
02/05/16Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization Therapy-Defibrillators
Amplia MRI(TM) and Compia MRI(TM) CRT-Ds, Approved for Patients with Heart Failure, Can Safely Undergo Full Body MRI Scans DUBLIN - Feb. 5, 2016 - Medtronic plc (NYSE:MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the first and only magnetic resonance imaging (MRI) conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure. The Medtronic Amplia MRI(TM) Quad CRT-D SureScan® and Compia MRI(TM) Quad CRT-... 
Download PDFPrinter Friendly Version
02/01/16Medtronic Adds New Resolute Onyx(TM) Drug-Eluting Stent Sizes and Expands Indications
New Extra-Large Vessel Stent Sizes and Indications in the EU Expand Treatment Options for Patients with Coronary Artery Disease DUBLIN - February 1, 2016 - Medtronic plc (NYSE: MDT) today announced the recent CE (Conformité Européene) Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next generation drug-eluting stent that is now available in 4.5mm and 5.0mm diameter sizes. The CE Mark also approved several new product indications including treatment of left mai... 
Download PDFPrinter Friendly Version
02/01/16Medtronic Adds Life-Extending Dialysis Portfolio to Recently Formed Renal Care Solutions Business with Acquisition of Bellco
DUBLIN - February 1, 2016 - Furthering its commitment to improve outcomes, expand therapy access, and optimize costs and efficiencies in end stage renal disease (ESRD), Medtronic plc (NYSE: MDT) today announced it acquired privately-held Bellco, a pioneer in hemodialysis treatment solutions.  Bellco's portfolio bolsters Medtronic's legacy renal access business and will be a foundational component of the company's recently formed Renal Care Solutions business.  Bellco has created therapies and ... 
Download PDFPrinter Friendly Version
01/30/16Medtronic Presents Innovation Village – The First-Of-Its-Kind Initiative – At The 2nd Medical Device Summit in New Delhi
NEW DELHI – 30 January 2016 – For the second year in a row, Medtronic hosted the Medical Device Summit in New Delhi on 30th January 2016, bringing together leading national and international healthcare practitioners, research scientists, and business leaders. The theme of this year’s Summit was “Technological Innovation,” and speakers shared their views and latest updates on innovation and clinical outcomes driving the evolution of the healthcare ecosystem. The Summit ad... 
Download PDFPrinter Friendly Version
01/29/16Medtronic to Present Data on Micra® Transcatheter Pacing System at Upcoming FDA Advisory Committee Meeting
DUBLIN - January 29, 2016 - Medtronic plc (NYSE: MDT) will present data on the world's smallest pacemaker, the Micra® Transcatheter Pacing System (TPS), at the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee on Feb. 18, 2016, in Gaithersburg, Maryland. According to the FDA, the committee will meet to discuss and make recommendations on clinical trial research, post-approval study design, and physician training requirements for le... 
Download PDFPrinter Friendly Version
01/13/16Medtronic Expands Pain Therapies Portfolio with the Launch of OsteoCool(TM) RF Ablation System
Minimally-Invasive Procedure Brings Relief to Patients Suffering from Painful Spine Tumors DUBLIN - January 13, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and U.S. launch of the OsteoCool(TM) RF Ablation System.  For physicians who treat patients with painful spine metastases, the OsteoCool System is the only cooled radiofrequency (RF) ablation technology that offers simultaneous, dual-probe capabilities - providing procedural flex... 
 Printer Friendly Version
01/11/16Medtronic Updates Capital Allocation Plans and Fiscal 2016 EPS Guidance
Executing Incremental $5 Billion Share Repurchase Tightening EPS Guidance Due to Benefit of U.S. R&D Tax Credit DUBLIN - Jan 11, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today updated its capital allocation plans for the approximately $9.3 billion resulting from the previously announced September 2015 internal reorganization as part of the company's integration of Covidien legal entities. Separately, the company today reiterated its re... 
Download PDFPrinter Friendly Version
01/11/16Medtronic IN.PACT Admiral DEB Receives CE Mark for Treatment of AV Access In Patients with End-Stage Renal Disease
IN.PACT Admiral DEB with 40 Centimeter Catheter Enables Physicians to Maintain Arteriovenous (AV) Access in Patients Undergoing Hemodialysis DUBLIN - January 11, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, today announced that the IN.PACT® Admiral® drug eluting balloon (DEB) (also known as the IN.PACT Admiral drug-coated balloon (DCB) in non-European markets) has received CE (Conformité Européene) Mark for arteriovenous (AV) access to help ma... 
Download PDFPrinter Friendly Version
01/11/16Medtronic and Chengdu Sign Insulin Pump Manufacturing Agreement
New Agreement Will Help Expand Access to Advanced Diabetes Therapies in China DUBLIN and CHENGDU, China - January 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has formed a partnership with the Chengdu municipal government to manufacture and deploy advanced diabetes therapies in Chengdu, China.  As part of the agreement, Medtronic will invest in a manufacturing facility for a next generation sensor augmented pump system with SmartGuard(TM) technology to help pro... 
Download PDFPrinter Friendly Version
X